- Severe leading to transplantation and death. Risk increased with > 2 weeks duration. Use only in life-threatening infections and in an inpatient facility. Should not be used when safer alternatives are available.
MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA
- Monitor LFTs in patients who develop signs/symptoms consistent with hepatitis. Consider discontinuing drug in patients who develop elevated LFTs.
Patient Counseling Information
Updated January 2018